Novartis AG (NOVN.SW) - Stock Analysis

Business Model

25%

3.5/5

3.51

Revenue is supported by chronic-therapy demand and four diversified therapeutic areas, with oncology ~31% of 2025 net sales ($16.8B of $54.5B). However, Q4 2025 Entresto sales fell 45% constant-currency to under $1.3B following July 2025 US LOE, demonstrating that predictability resets at patent expiry. Gross margins are structurally high and the company delivered a 40.1% core operating margin in 2025.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.00

Forward visibility of revenue: backlog, contracts, retention

3.00

Summary

Chronic-disease prescriptions provide baseline visibility, but Q4 2025 showed Entresto sales collapsing 45% cc to sub-$1.3B after July 2025 US LOE — structural patent-cliff step-downs limit forward visibility despite in-patent stability.

3.00

Product Diversification10%

3.25

Diversification across product lines, segments, and customers

3.25

Summary

Four therapeutic areas (oncology ~31% of 2025 revenue, plus immunology, neuroscience, CVRM). Cosentyx at ~$6.7B and Kisqali at ~$4B are sizable but no single drug exceeded ~15% of 2025 sales post-Entresto erosion.

3.25

Geographic Diversification15%

3.25

Distribution across regions and home-market dependence

3.25

Summary

United States produced $21.1B of 2024 net sales (~42% of total) with the balance from Europe, China, Japan and other markets. Exposure is meaningful but not dominant in any single country.

3.25

Scalability20%

3.75

Ability to grow revenue without proportional cost increases

3.75

Summary

Drug manufacturing carries low marginal cost relative to price, producing structurally high gross margins; Novartis reached a 40.1% core operating margin in 2025 despite rising generic erosion, reflecting operating leverage on a fixed cost base.

3.75

Revenue Quality25%

3.50

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.50

Summary

Prescription revenue is largely non-discretionary and recurring at the patient level for chronic indications like heart failure, MS, and psoriasis. Nature of revenue is insurance-reimbursed rather than contractual, and duration is capped by patent life.

3.50

Competitive Advantages

40%

The competitive moat is narrower than the business profile suggests. Patent protection provides temporary exclusivity rather than durable lock-in, and the 2025-2026 patent cliff (Entresto, Promacta, Tasigna) demonstrates how quickly revenue evaporates at LOE. Innovation pipeline is the principal durable advantage; pricing power, switching costs, and brand strength at the corporate level are limited.

Pro dimensions

Competitive Advantages · Management · Risk Assessment